Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-26T08:31:30.827Z Has data issue: false hasContentIssue false
  • English
  • Français

Disclosing the extensive crystal chemistry of Ivabradine hydrochloride, in its pure and solvated phases

Published online by Cambridge University Press:  23 July 2013

N. Masciocchi ,
A. Aulisio ,
G. Bertolini ,
M. Sada ,
F. Garis  and
L. Malpezzi
N. Masciocchi*
Affiliation:
Dipartimento di Scienza e Alta Tecnologia, Università dell'Insubria, via Valleggio 11, 22100 Como, Italy
A. Aulisio
Affiliation:
Dipartimento di Scienza e Alta Tecnologia, Università dell'Insubria, via Valleggio 11, 22100 Como, Italy
G. Bertolini
Affiliation:
Labochim spa, Via B. Cellini, 20, 20090, Segrate, Italy
M. Sada
Affiliation:
Labochim spa, Via B. Cellini, 20, 20090, Segrate, Italy
F. Garis
Affiliation:
Labochim spa, Via B. Cellini, 20, 20090, Segrate, Italy
L. Malpezzi
Affiliation:
Dipartimento di Chimica, Materiali e Ingegneria Chimica “Giulio Natta”, Politecnico di Milano, via Mancinelli 7, 20131 Milano, Italy
*
a) Author to whom correspondence should be addressed. Electronic mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Powder diffraction data are presented for Ivabradine hydrochloride (pure and solvated forms), a drug marketed worldwide for symptomatic treatment of angina pectoris and inappropriate sinus tachycardia. [Ivrabradine: 3-[3-({[(7S)-3,4-dimethoxy bicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino)propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one]. Many are the different (polymorphic or solvated) phases claimed in the scientific or forensic literature. We have here prepared monophasic samples of six different ivabradine hydrochloride species. Exposure to water vapours, at room temperature, of the anhydrous δ-d form generated pure powders of the tetrahydrate form (the β-form). Two different anhydrous forms (β-d and α) were prepared by gentle, or extensive, heating of the β and δ-d forms, respectively. Acetonitrile and acetone solvates (hereafter called δ1- and δ2-forms) were obtained by precipitation methods from concentrated solutions. Diffraction data were collected on laboratory equipment with Ni-filtered CuKα radiation; cell parameters and space groups were determined from ab initio indexing procedures using the SVD algorithm.

Keywords

ivabradine hydrochloridedrugpolymorphic formssolvatesXRPD
Type
Technical Articles
Information
Powder Diffraction , Volume 28 , Issue 3 , September 2013 , pp. 200 - 206
Copyright
Copyright © International Centre for Diffraction Data 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Cheary, R. W. and Coelho, A. (1992). “A fundamental parameters approach to X-ray line profile fitting”, J. Appl. Crystallogr. 25, 109–121.CrossRefGoogle Scholar
Coelho, A. (2003). “Indexing of powder diffraction patterns by iterative use of singular value decomposition”, J. Appl. Crystallogr. 36, 85–95.CrossRefGoogle Scholar
De Wolff, P. M. (1972). “A simplified criterion for the reliability of a powder pattern indexing”, J. Appl. Crystallogr., 1, 108–113.CrossRefGoogle Scholar
Duval, D., Hennig, P., Bouchet, J. P., Vian, J., Peglion, J. L., Volland, G. P., Platzer, N., and Guilhem, J. (1997). “Stereochemical study of bradicardisant benzazepine-type drug. X-ray structure of the chloride salt and high-field NMR study of the stereochemistry in solution”, Magn. Res. Chem. 35, 175–183.3.0.CO;2-5>CrossRefGoogle Scholar
Dwivedi, S. D., Kumar, R., Patel, S. T., and Shah, A. P. C. (2008). “Process for preparation of ivabradine hydrochloride” International Patent WO 065681 A2, (δ-d-form).Google Scholar
Horvath, S., Auguste, M.-N., and Damien, G. (2006). “Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it” US Patent 0194962 A1.Google Scholar
Horvath, S., Auguste, M.-N., and Damien, G. (2007). “Delta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it” US Patent 0082885 A1.Google Scholar
Horvath, S., Auguste, M.-N., and Damien, G. (2011). “β D-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it” US Patent 7867995.Google Scholar
Singh, S. P., Singh, G., and Wadhwa, L. (2012). “Crystalline ivabradine oxalate salts and polymorphs thereof”, European Patent EP 2471780 (α-form).Google Scholar
TOPAS-R, v. 3.0, (2005). Bruker AXS, Karlsruhe, GermanyGoogle Scholar
Wieser, J., Griesser, U., Enders, M., and Kahlenberg, V. (2013). “Acetone solvate of ivabradine hydrochloride”, Patent WO2013/017582.Google Scholar